Targeting cancer testis antigens in synovial sarcoma
Synovial sarcoma (SS) is a rare cancer that disproportionately affects children and young adults. Cancer testis antigens (CTAs) are proteins that are expressed early in embryonic development, but generally not expressed in normal tissue. They are aberrantly expressed in many different cancer types a...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/6/e002072.full |
id |
doaj-34ea381131884667ba1b55b4a357b96e |
---|---|
record_format |
Article |
spelling |
doaj-34ea381131884667ba1b55b4a357b96e2021-08-01T11:30:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-06-019610.1136/jitc-2020-002072Targeting cancer testis antigens in synovial sarcomaGeoffrey Mitchell0Seth M Pollack1Michael J Wagner2University of Washington, Spokane, Washington, USAClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USAClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USASynovial sarcoma (SS) is a rare cancer that disproportionately affects children and young adults. Cancer testis antigens (CTAs) are proteins that are expressed early in embryonic development, but generally not expressed in normal tissue. They are aberrantly expressed in many different cancer types and are an attractive therapeutic target for immunotherapies. CTAs are expressed at high levels in SS. This high level of CTA expression makes SS an ideal cancer for treatment strategies aimed at harnessing the immune system to recognize aberrant CTA expression and fight against the cancer. Pivotal clinical trials are now underway, with the potential to dramatically alter the landscape of SS management and treatment from current standards of care. In this review, we describe the rationale for targeting CTAs in SS with a focus on NY-ESO-1 and MAGE-A4, the current state of vaccine and T-cell receptor-based therapies, and consider emerging opportunities for future development.https://jitc.bmj.com/content/9/6/e002072.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Geoffrey Mitchell Seth M Pollack Michael J Wagner |
spellingShingle |
Geoffrey Mitchell Seth M Pollack Michael J Wagner Targeting cancer testis antigens in synovial sarcoma Journal for ImmunoTherapy of Cancer |
author_facet |
Geoffrey Mitchell Seth M Pollack Michael J Wagner |
author_sort |
Geoffrey Mitchell |
title |
Targeting cancer testis antigens in synovial sarcoma |
title_short |
Targeting cancer testis antigens in synovial sarcoma |
title_full |
Targeting cancer testis antigens in synovial sarcoma |
title_fullStr |
Targeting cancer testis antigens in synovial sarcoma |
title_full_unstemmed |
Targeting cancer testis antigens in synovial sarcoma |
title_sort |
targeting cancer testis antigens in synovial sarcoma |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2021-06-01 |
description |
Synovial sarcoma (SS) is a rare cancer that disproportionately affects children and young adults. Cancer testis antigens (CTAs) are proteins that are expressed early in embryonic development, but generally not expressed in normal tissue. They are aberrantly expressed in many different cancer types and are an attractive therapeutic target for immunotherapies. CTAs are expressed at high levels in SS. This high level of CTA expression makes SS an ideal cancer for treatment strategies aimed at harnessing the immune system to recognize aberrant CTA expression and fight against the cancer. Pivotal clinical trials are now underway, with the potential to dramatically alter the landscape of SS management and treatment from current standards of care. In this review, we describe the rationale for targeting CTAs in SS with a focus on NY-ESO-1 and MAGE-A4, the current state of vaccine and T-cell receptor-based therapies, and consider emerging opportunities for future development. |
url |
https://jitc.bmj.com/content/9/6/e002072.full |
work_keys_str_mv |
AT geoffreymitchell targetingcancertestisantigensinsynovialsarcoma AT sethmpollack targetingcancertestisantigensinsynovialsarcoma AT michaeljwagner targetingcancertestisantigensinsynovialsarcoma |
_version_ |
1721245864363556864 |